Malignant News and Research

RSS

Microchip to track genetic signature of cancer and normal tissue

MicroRNAs (miRNAs), tiny pieces of genetic material that can serve as stop signs for gene expression and protein synthesis, are thought to be important in the development of cancer.

23 Jun 2004

Partial breast radiation procedure may benefit cancer patients

Some women with breast cancer who prefer breast conserving surgery consisting of lumpectomy and radiation may choose a procedure that delivers radiation to the malignant tumor and not to the entire breast

23 Jun 2004

New computer cluster will help understanding of how human cells and organs work

A new computer cluster funded by the University of Sheffield and located within the Royal Hallamshire Hospital, will help scientists to improve their understanding of how human cells and organs work.

22 Jun 2004

Early patient response to Forteo in postmenopausal women with osteoporosis

Changes in markers of bone remodeling after one month of treatment with FORTEO® (teriparatide [rDNA origin] injection) may provide important early evidence of treatment response, according to new data presented today at the 86th Annual Meeting of The Endocrine Society (ENDO).

17 Jun 2004

Computer cluster helps understand how human cells and organs work

This will ultimately lead to more effective ways of treating cardiovascular disease and cancer as well as other diseases. It will also eventually allow doctors to tailor treatment in a way specific to that patient rather than a ‘one-size-fits-all’ approach.

17 Jun 2004

New target to stop breast cancer growth

Two proteins that normally help cells move from place to place and are made in large quantities in breast cancer cells work together to promote the survival and spread of breast cancer, according to a new study by scientists at The University of Texas M. D. Anderson Cancer Center.

15 Jun 2004

Identification of early ovarian cancer symptoms may have important clinical implications

Symptoms experienced by women that are more severe or frequent than expected and of recent occurrence warrant further diagnostic investigation because they are more likely to be associated with both benign (non-cancerous) and malignant (cancerous) ovarian masses

14 Jun 2004

Magnetic resonance imaging better than traditional mammography for detecting the presence of breast cancer

Researchers from the Abramson Cancer Center of the University of Pennsylvania today presented the first comprehensive study results which show that magnetic resonance imaging (MRI) is significantly better than traditional mammography for detecting the presence and extent of disease in patients with a diagnosis of breast cancer.

10 Jun 2004

Advertising restrcitions on some over the counter medicines likely to be lifted

Regulations to remove the current ban on advertising certain over the counter (OTC) medicines to the public were laid in Parliament today

9 Jun 2004

A biological agent used without chemotherapy appears to offer a disease-free future to patients with rare leukemia

A biological agent — a drug that wraps vitamin A inside bubbles of fat — used without chemotherapy appears to offer as many as one-third of patients with a rare form of leukemia an opportunity for a long-term, disease-free future, say researchers at The University of Texas M. D. Anderson Cancer Center.

7 Jun 2004

Drug Tarceva improves survival chance for patients with advanced lung cancer

Roche OSI Pharmaceuticals and Genentech today announced that their investigational drug Tarceva(TM) (erlotinib) achieved a significant 42.5% improvement in median survival compared to placebo in patients with advanced non-small cell lung cancer (NSCLC).

5 Jun 2004

Understanding focal adhesion kinase (FAK) may lead to new cancer treatments

Scientists at the University of North Carolina at Chapel Hill have found an unexpected way to turn off a cellular enzyme involved in the progression of several types of human cancers.

2 Jun 2004

Tobacco-related illnesses costs Ilinois $6.7 billion annually

Tobacco-related illnesses take the lives of more than 16,500 Illinois residents each year and cost the state $6.7 billion annually in medical care and lost productivity, according to Dr. Eric E. Whitaker, state public health director.

27 May 2004

New target of a cancer-causing gene

Researchers from the Johns Hopkins Bloomberg School of Public Health and other institutions have identified a new target of a cancer-causing gene.

27 May 2004

Evidence that abnormally short telomeres play a role in the early development of cancer

Scientists at the Johns Hopkins Kimmel Cancer Center say they have evidence that abnormally short telomeres - the end-caps on chromosomes that normally preserve genetic integrity -appear to play a role in the early development of many types of cancer.

27 May 2004

Study finds breast cancer in men is increasing though the disease remains rare

The largest study to date of male breast cancer finds, contrary to previous reports, breast cancer rates in men are increasing though the disease remains rare.

23 May 2004

Patients with leukemia or lymphoma who undergo hematopoietic-cell transplantation and survive can expect full recovery to take 3-5 years

Patients with leukemia or lymphoma who undergo hematopoietic-cell transplantation (HCT) and survive can expect full recovery to take 3-5 years, according to a study published in the May 19 issue of The Journal of the American Medical Association (JAMA).

19 May 2004

Chromosome losses can signal an especially poor response to therapy

A new international study of children with a severe form of acute lymphoblastic leukemia(ALL) shows that certain chromosome losses can signal an especially poor response to therapy, but that other chromosome abnormalities have no effect on treatment survival.

13 May 2004

Phase 3 trial of Ceplene in acute myeloid leukemia meets primary trial endpoint

Maxim Pharmaceuticals has announced the results of an international Phase 3 clinical trial testing the combination of Ceplene (TM) plus interleukin-2 (IL-2) in 320 patients with acute myeloid leukemia (AML) in complete remission.

12 May 2004

Restrictions by health insurers and government to control expenses may hurt the malignant melanoma drug market

Decision Resources, Inc., a research and advisory firms focusing on pharmaceutical and health care issues, finds that restrictions by health insurers and government health authorities to control expenses may hurt the malignant melanoma drug market.

12 May 2004